Erlotinib: Difference between revisions
Jump to navigation
Jump to search
David Canner (talk | contribs) No edit summary |
David Canner (talk | contribs) No edit summary |
||
| Line 3: | Line 3: | ||
* Marketed By: Genentech, OSI Pharmaceutials, & Roche | * Marketed By: Genentech, OSI Pharmaceutials, & Roche | ||
* Major Indication: Pancreatic & Small Cel Lung [[Cancer]] | * Major Indication: Pancreatic & Small Cel Lung [[Cancer]] | ||
* Drug Class: EGFR Inhibitor | * Drug Class: [[EGFR]] Inhibitor | ||
* Date of FDA Approval (Expiration): 2005 (2020) | * Date of FDA Approval (Expiration): 2005 (2020) | ||
* 2009 Sales: $1.2 Billion | * 2009 Sales: $1.2 Billion | ||